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Cardioplegic arrest provides essential cardioprotectionduring cardiac operations, and advantages of continu-
ous warm blood cardioplegia have been advanced for
minimizing ischemia and avoiding risks related to
hypothermia. However, postoperative ventricular dys-
function and injury caused by prolonged cardiac arrest led
to the development of additional cardioprotective strate-
gies.1,2 Adenosine triphosphate–dependent potassium
(KATP) channel openers have been shown to limit contrac-
tile dysfunction,3-5 infarct size,6 and cellular energy deple-
tion7,8 caused by ischemia-reperfusion. Moreover, experi-
mental studies carried out on the rabbit,9 pig,10 guinea
pig,11,12 and rat13 have demonstrated benefits of KATP
channel activators to improve myocardial preservation
provided by both cold and warm cardioplegia.
Objectives: Although adenosine triphosphate–dependent potassium channel
openers have been shown to enhance cardioplegic protection in animal
myocardium, there is a lack of data on human cardiac tissues. We aimed at
determining, on human atrial muscle, whether adenosine triphosphate–
dependent potassium channels are involved in protection caused by high-
potassium cardioplegia and whether adenosine triphosphate–dependent
potassium channel activation might improve cardioplegic protection in an in
vitro model of myocardial stunning.
Methods: Human atrial trabeculae were obtained from adult patients under-
going cardiac operations. In an organ bath at 37°C, the preparations were
subjected to 60 minutes of hypoxia at a high stimulation rate either in Tyrode
solution (control, n = 17) or in St Thomas’ Hospital solution without addi-
tives (n = 6) or associated with 100 nmol/L bimakalim (n = 7) or 1 µmol/L
glibenclamide (n = 7), followed by 60 minutes of reoxygenation and 15 min-
utes of positive inotropic stimulation with 1 µmol/L dobutamine.
Results: Atrial developed tension was reduced by hypoxia to 27% ± 5% of
baseline and incompletely recovered after reoxygenation to 38% ± 7%,
whereas dobutamine restored contractility to 74% ± 7% of basal values. St
Thomas’ Hospital solution with or without bimakalim improved developed
tension after reoxygenation and dobutamine (P < .0001 vs control), whereas
glibenclamide inhibited these protective effects of cardioplegic arrest (P =
.001 vs St Thomas’ Hospital solution). After reoxygenation, the protective
effect of bimakalim disappeared at a high pacing rate (400- and 300-ms cycle
length) but recovered during dobutamine superfusion.
Conclusions: Adenosine triphosphate–dependent potassium channels are
likely involved in the cardioprotective effects of cardioplegia in human atri-
al trabeculae and adenosine triphosphate–dependent potassium channel acti-
vation with bimakalim used as an additive to cardioplegia enhanced protec-





Saverio La Francesca, MD
Giovanni Ruvolo, MD
Ugo Papalia, MD
Pietro Paolo Campa, MD
Benedetto Marino, MD
Paolo Emilio Puddu, MD
From the Laboratory of Cardiovascular Pharmacology, Department of
Cardiac Surgery and Second Section of Cardiology, University of
Rome “La Sapienza,” Rome, Italy.
Supported in part by Ministero dell’Università e della Ricerca
Scientifica, Rome (Ricerche di Ateneo 145/1997) and by
Cardioricerca, Rome, Italy. Dr Wagner from E. Merck, Darmstadt,
Germany, provided a gift of bimakalim used in this study.
Received for publication April 20, 1999; revisions requested June 3,
1999; revisions received Dec 1, 1999; accepted for publication
Dec 7, 1999.
Address for reprints: Paolo Emilio Puddu, MD, FESC, FACC, Istituto
di Chirurgia del Cuore e Grossi Vasi, II Cattedra di Cardiologia,
Università degli Studi di Roma “La Sapienza,” Viale del
Policlinico, 155, Rome 00161, Italy (E-mail: puddu.pe@iol.it).
Copyright © 2000 by The American Association for Thoracic
Surgery.
0022-5223/2000 $12.00 + 0 12/1/104878
doi:10.1067/mtc.2000.104878
ADENOSINE TRIPHOSPHATE–DEPENDENT POTASSIUM CHANNEL MODULATION AND 
CARDIOPLEGIA-INDUCED PROTECTION OF HUMAN ATRIAL MUSCLE IN AN IN VITRO MODEL OF
MYOCARDIAL STUNNING
The Journal of Thoracic and
Cardiovascular Surgery
Volume 119, Number 4, Part 1
Monti et al 843
The susceptibility to ischemic injury and responsive-
ness to myocardial protection, however, differ among
mammals,14 and the efficacy of a KATP channel opener
on cardiac muscle may differ between human and other
species, as we demonstrated in a previous work.15
Considering that the goal of experimental studies on
cardioplegia is use in the human myocardium and
determination of the potential benefits that patients
might find in strategies aimed at reducing postoperative
myocardial stunning, confirmation on human cardiac
muscle of protective action of KATP channel openers as
additives to cardioplegic solution is of interest.
We aimed at determining whether KATP channels are
implicated in the cardioprotective effects of cardio-
plegic arrest with St Thomas’ Hospital solution (STHS)
superfusion on human atrial trabeculae and whether
KATP channel activation may enhance the benefits of
cardioplegia against myocardial stunning induced by
hypoxia-reoxygenation. For this, we used the selective
KATP channel blocker glibenclamide and the KATP chan-
nel opener bimakalim as additives to the cardioplegic
solution during the hypoxic phase. Normothermic
instead of cold cardioplegia was selected to prevent
complicating factors related to temperature shift in the
analysis of contractility changes among experimental
groups.12
Patients and methods
Preparation. Informed consent was obtained from 41
adult patients (68% male and 32% female subjects) undergo-
ing elective cardiac operations, whose ages ranged from 23 to
79 years (57 ± 11 years) and who had coronary artery disease
(59%), rheumatic valve disease (34%), or congenital lesions
(7%). Patients were routinely taking cardioactive drugs
according to standard prescriptions. Ethical considerations
prevented us from stopping these drugs more than 24 hours
before the operations. Exclusion criteria were arrhythmia,
right ventricular failure, and antiarrhythmic or oral hypo-
glycemic medication. Premedication, given 1 hour before
induction of anesthesia, usually consisted of diazepam,
antibiotic (cephalotine), and aprotinin. General anesthesia
was then induced with diazepam, fentanyl, pancuronium, and
sometimes nitrous oxide.
A sample of the right atrial appendage (approximately 1
cm2, 500-1000 mg) was removed and immersed in preoxy-
genated modified Tyrode solution (NaCl, 120 mmol/L; KCl,
4 mmol/L; CaCl2, 2.7 mmol/L; MgCl2, 1.1 mmol/L;
NaHCO3, 25.7 mmol/L; NaH2PO4, 1.8 mmol/L [pH 7.4]; and
glucose, 11 mmol/L) at room temperature.5,15-18 Free-running
trabeculae were isolated and fixed to a precalibrated force
Fig 1. Experimental protocol for investigation of protective effects of normothermic (37°C) cardioplegia (STHS),
either alone or associated with KATP channel modulators, on human atrial trabeculae in an in vitro model of
myocardial stunning. FF relationships were studied after each different experimental phase. Hypoxia was per-
formed at a high pacing rate (400-ms CL).
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transducer (TRN001; Kent Scientific Corporation) in an
organ bath, where the preparation was superfused at 5
mL/min with Tyrode solution gassed with 95% oxygen and
5% carbon dioxide (PO2, 500 mm Hg measured at 755 mm
Hg of barometric pressure) and gradually warmed up (circu-
lating thermostat-regulated bath: Polystat 86602, Bioblock
Scientific) to 37°C.
Stimulation and recordings. The muscle was stimulated
at 1600 ms of basal cycle length (CL) by means of a bipolar
Teflon-coated 99.99% silver wire electrode (AG-15T, 0.375
mm in diameter; PHYMEP sarl). Square pulses of 1-ms dura-
tion and 4-mA intensity were delivered by an orthorhythmic
stimulator (Explorer 1000, VPA Medical). The trabecula was
lengthened to the top of its length-tension curve. Isometric
force development was monitored on a digital memory oscil-
loscope (Tektronix 2230, Tektronix Inc), and data were digi-
tized at a sampling frequency of 8 KHz (Datapac 13.2,
Biologic). The software automatically measured developed
tension (DT) and time to peak tension. After the experiment,
the contracting trabecular portion was dried and weighed on
a precise balance (Sartorius BA 110S, Sartorius AG).
Experimental protocol (Fig 1). In a time-related control
group (TRC group, n = 17), we assessed the time-dependent
contractility loss of trabecular strips stimulated at 1600-ms
CL. Thereafter the Paradise test19 was performed in 10 prepa-
rations included in the latter group, changing 95% oxygen
and 5% carbon dioxide in Tyrode solution to 80% oxygen,
5% carbon dioxide, and 15% nitrogen for 15 minutes.
Another 17 trabeculae were subjected to 60 minutes of
hypoxia at 400-ms CL by superfusion with nonoxygenated
Tyrode solution (PO2 180 mm Hg) and then returned to nor-
mal for 60 minutes (reoxygenation phase), after which they
were subjected to 1 µmol/L dobutamine for 15 minutes. The
same protocol was achieved for another 20 preparations
undergoing the hypoxic phase at a high pacing rate under nor-
mothermic cardioplegia by superfusion with nonoxygenated
hyperkalemic STHS,20 either without additive (STHS, n = 6)
or in the presence of 100 nmol/L bimakalim (E. Merck
Laboratories; n = 7) or 1 µmol/L glibenclamide prediluted in
dimethylsulfoxide 0.01% (Sigma Chemical Co; n = 7). At
0.01%, dimethylsulfoxide 0.0% had no significant effect on
human atrial contractility. The composition of STHS was as
follows: NaCl, 110 mmol/L; KCl, 16 mmol/L; CaCl2, 1.2
mmol/L; MgCl2, 16 mmol/L; and NaHCO3, 10 mmol/L (pH
7.8). High stimulation rate (400-ms CL) was used during the
hypoxic phase to raise the severity of hypoxia, leading to
stunned human atrial muscle.5,16,17 Stimulation was contin-
ued during cardioplegia to maintain the experimental condi-
Fig 2. Effects of hypoxia-reoxygenation and dobutamine challenge on human atrial contractility. DT variations
are expressed as means ± SEM. P values refer to ANOVA for repeated measures performed for the 4 hypoxia-
related groups: control, STHS, STHS plus bimakalim, and STHS plus glibenclamide. TRCs are included for visu-
al comparative purposes. Note highly significant P values for group (G), time (T) and group · time (G*T) factors.
Note marked positive inotropic action of dobutamine in preparations subjected to cardioplegic arrest, either alone
or in the presence of 100 nmol/L bimakalim, whereas 1 µmol/L glibenclamide inhibited protective effects of car-
dioplegia after hypoxia.
The Journal of Thoracic and
Cardiovascular Surgery
Volume 119, Number 4, Part 1
Monti et al 845
A
B
Fig 3. Changes of velocity of tension developed by human
atrial trabeculae after hypoxia-reoxygenation and dobuta-
mine challenge. Values of log[velocity of DT] are expressed
as means ± SEM. For comparison, 95% confidence intervals
of basal values for all 54 preparations included in the ran-
domized study are shown in gray. A, *P < .05 and **P < .01
versus control, Student t test with Bonferroni correction.
Note that 100 nmol/L bimakalim added to cardioplegic solu-
tion significantly improved the velocity of DT after hypoxia-
reoxygenation and dobutamine challenge. B, *P < .05 and
**P < .005 versus base, Student t test for paired data. Note
that velocity of DT was decreased after dobutamine challenge
when 1 µmol/L glibenclamide was associated with cardiople-
gia, and conversely it was improved in the STHS plus
bimakalim group (P < .05, Fisher exact test).
Fig 4. Changes in FF relationships of human atrial trabeculae
after reoxygenation (A) and dobutamine challenge (B) in
control and STHS-related groups. Developed tension varia-
tion (%DT) of DT measured during basal FF at correspond-
ing cycle length is expressed as means ± SEM. P values refer
to ANOVA for repeated measures performed for the 4 groups.
Note higher FF-related developed tension variation after car-
dioplegic treatment, either alone or in the presence of 100
nmol/L bimakalim, than in the control and STHS plus gliben-
clamide groups, which fits with improved human atrial con-
tractility, as illustrated in Fig 2. Note that the protective effect
of STHS plus bimakalim after reoxygenation disappeared at
the high pacing rate (A), whereas after dobutamine treatment
(B), there was no such interference.
A
B
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tions similarly to the other groups (TRC and control groups).
A previous study showed that the in vitro contractile protec-
tion afforded by STHS was independent of pacing during car-
dioplegic arrest.12 As previously discussed,5,17 in this model
the stunning phenomenon was disclosed by 1 µmol/L dobuta-
mine challenge, testing the reversibility of the hypoxia/reoxy-
genation–induced contractile dysfunction. After each experi-
mental phase, the force-frequency (FF) relationship was
studied by decreasing stimulation CL from 1600 ms to 1200,
1000, 800, 400, and 300 ms.12,17
Statistics. Data shown in Table I are expressed as means ±
SD, and data shown in Figs 1 to 4 and text are expressed as
means ± SEM. Analysis of variance (ANOVA) was per-
formed to compare basal characteristics of preparations
(Table I, 1-way ANOVA) and DT variations among groups
(Figs 2 and 4, ANOVA for repeated measures). A variable
was created to index trabecular number and thus account for
the lack of independence caused by two trabeculae from the
same patient in 13 of 54 preparations. Covariance for this
variable did not, however, add any statistical contribution in
the above-mentioned repeated measures ANOVA models
where it was tested (BMDP-5V). The Student t test with
Bonferroni correction, the Student t test for paired values, and
the Fisher exact test were used for analysis of changes in log
[velocity of DT] (Fig 3).
Results
Characteristics of human atrial trabeculae. Basal
characteristics of the human atrial trabeculae used in
this randomized study are summarized in Table I.
DT of atrial preparations exposed to oxygenated
Tyrode solution (TRC group) decreased to 91% ± 5%
after 60 minutes and to 73% ± 7% after 135 minutes
(Fig 2), corresponding to an attrition rate of 9% during
the first hour and 15% per hour thereafter. After 15
minutes of the Paradise test, trabecular DT was reduced
to 74% ± 4% of DT values measured before the test.
Effects of cardioplegia and KATP channel modu-
lators on human trabecular contractility during
hypoxia-reoxygenation and dobutamine challenge.
After 60 minutes of hypoxia at a high pacing rate (Fig
2, control), DT was lessened to 27% ± 5% of basal
values and recovered slightly only after reoxygena-
tion to 38% ± 7% before reaching 74% ± 7% of basal
DT after dobutamine, and this was similar to values
measured in the TRC group. After cardioplegic arrest,
during reoxygenation and dobutamine challenge, DT
was significantly improved in the STHS and STHS
plus bimakalim groups (both P < .0001 versus con-
trol), whereas the percentage of DT observed in the
STHS plus glibenclamide group was similar to that
found in the control group (P = .12), demonstrating
that glibenclamide inhibited the protective effect of
cardioplegic arrest (P = .001 vs STHS). Also, on
velocity of DT, bimakalim lessened the decrease
induced by hypoxia-reoxygenation (Fig 3, A) and
enhanced velocity of DT after dobutamine (Fig 3, A
and B), whereas velocity of DT was reduced in the
control and STHS plus glibenclamide groups com-
pared with basal values (Fig 3, B).
FF relationships. Before hypoxia, human atrial tra-
beculae exhibited a slight positive FF relationship as
CL decreased until 800 ms, and then depressed DT was
seen at the high pacing rate. At low frequency, the FF
relationship became negative after hypoxia (P = .004 vs
baseline) and returned to positive after reoxygenation.
After dobutamine, no DT reduction occurred at the
highest stimulation frequencies (P < .005 vs baseline).
Table I. Basal characteristics (pacing, 1600-ms CL; 37°C) of human atrial trabeculae used in the randomized
study
STHS + STHS + 
bimakalim glibenclamide 
Total TRC Control STHS 100 nmol/L 1 µmol/L 
Variables (n = 54) (n = 17) (n = 17) (n = 6) (n = 7) (n = 7) P values
Age of patients (y) 57 ± 11 (n = 41) 55 ± 14 58 ± 14 56 ± 6 54 ± 8 62 ± 6 .8
Mass (mg) 29 ± 19 32 ± 23 31 ± 23 28 ± 13 20 ± 7 23 ± 6 .6
Length (mm) 5.5 ± 2.2 6.1 ± 2.7 5.8 ± 2.7 5.8 ± 1.2 4.3 ± 0.5 4.6 ± 0.8 .3
Cross-sectional area (mm2) 2.6 ± 2.3 2.9 ± 2.6 2.8 ± 2.6 3.0 ± 2.3 1.5 ± 1.2 2.1 ± 1.3 .6
DT (mN) 6.8 ± 4.9 9.3 ± 5.8 5.1 ± 4.6 5.3 ± 4.2 5.5 ± 2.1 7.4 ± 3.5 .09
velDT (mN/s)* 57 ± 39 76 ± 48 45 ± 38 44 ± 31 44 ± 17 63 ± 25 .12
DTi (mN/mm2)† 4.6 ± 4.1 6.2 ± 5.2 3.2 ± 3.0 2.2 ± 1.5 5.7 ± 3.5 4.7 ± 3.7 .11
velDTi (mN/s·mm2)† 40 ± 35 51 ± 42 30 ± 29 19 ± 15 49 ± 31 44 ± 39 .2
Data are expressed as means ± SD. P values refer to analysis of variance among the 5 groups. DT, Developed tension; velDT, Velocity of developed tension; DTi,
indexed DT; velDTi, indexed velDT.
*velDT was measured as DT/time to peak tension.
†DTi and velDTi were measured as DT/cross-sectional area and velDT/cross-sectional area, respectively.
After reoxygenation (Fig 4, A), the improved DT
observed at the low pacing rate in the STHS plus
bimakalim group (P < .005 vs control) disappeared at
rapid pacing (400- and 300-ms CL). After 1 µmol/L
dobutamine (Fig 4, B), at short CL, all groups showed
DT values higher than DT values obtained during basal
FF at corresponding CL (P < .0001 for time factor),
and the enhanced DT induced by STHS plus
bimakalim treatment remained during the high pacing
rate also.
Discussion
This in vitro study shows that (1) KATP channels are
likely involved in the cardioprotective effects of car-
dioplegic arrest in stunned human atrial muscle
because the contractile protection was inhibited by
glibenclamide and (2) KATP channel activation by
bimakalim, used as an additive of STHS, may enhance
the human atrial protection caused by cardioplegic
arrest. This latter additional benefit was, however, abol-
ished by the high pacing rate after hypoxia-reoxygena-
tion but was present after dobutamine challenge, even
at rapid pacing. Changes in FF relationship were
superposable to variations reported previously,17 show-
ing that the negative inotropic action of a high pacing
rate (400- and 300-ms CL), likely because of dramatic
shortening of human atrial action potential dura-
tion,17,18 consists of a normal physiologic adaptation of
human atrial contractile function to rapid pacing. More
interesting were the negative FF relationships induced
by hypoxia and then reversed after reoxygenation and
the abolition of the negative inotropic action of the high
pacing rate by dobutamine, as observed in the rabbit
heart.21 Considering that our findings in human cardiac
tissue arise from a model of normothermic continuous
STHS delivery, it will be important to confirm the addi-
tional protective effects of bimakalim during other car-
dioplegic methods, such as cold cardioplegia, because
it has been reported extensively, although only in ani-
mal preparations.9-12
Although data suggest that KATP channels are likely
involved in cardioprotective mechanisms related to nor-
mothermic cardioplegia in human atrial myocardium, it
is unclear whether sarcolemmal KATP channels alone are
implicated or whether the mitochondrial channels also
may play a role. A recent animal study showed that
diazoxide, a specific mitochondrial KATP opener, may
exert cardioprotective effects, whereas 5-OH-
decanoate, a mitochondrial KATP blocker, may block
cardioprotection.22 Animal studies already reported
benefits with other KATP channel openers as additives of
cardioplegic solutions9,10 and particularly advantages of
nicorandil.11-13,23 We chose bimakalim, which exerts
selective KATP channel activating action, as opposed to
nicorandil, which also possesses nitrate-related proper-
ties. In addition, we used a relatively low concentration
(100 nmol/L) of bimakalim on the basis of the previous
studies demonstrating protective effects of bimakalim
on human atrial contractile function5 at concentrations
(10-100 nmol/L) devoid of negative inotropic action and
depressant effect on human atrial action potential dura-
tion.5,15 Indeed, it is important that additive cardiopro-
tection may be obtained in the absence of action poten-
tial changes, thus ruling out potential proarrhythmic
risks related to KATP channel activators.24,25 Moreover,
the bimakalim concentration used here may be consid-
ered relevant for the clinical setting. Senior and associ-
ates26 reported bimakalim plasmatic concentrations of
about 50 nmol/L in normal volunteers. Further studies
are now needed to clarify the mechanisms involved in
the bimakalim-induced protection during cardioplegia.
In view of the strong pharmacologic evidence that KATP
channels are involved, mitochondrial KATP channel is a
strong candidate for the putative end effector of
bimakalim-induced benefits27 because additive protec-
tion was obtained during cardioplegic arrest and there-
fore in absence of any contractile and electrical activity.
The additional cardioprotective effects of bimakalim
disappeared during the high pacing rate just after
hypoxia-reoxygenation, whereas positive inotropic
stimulation with dobutamine restored these effects.
These findings may suggest that additional benefits of
KATP channel activation might be overshadowed in the
presence of high heart rate, arrhythmic events, or both
after hypoxia-reoxygenation where contractile function
is about to recover. Although caution is needed when
extrapolating in vitro findings to clinical situations,
these data support the usefulness of FF relationship
studies when investigating the effects of KATP channel
openers. Otherwise, the restoration of bimakalim’s pro-
tective effects by dobutamine at high pacing may be
due to the positive inotropic stimulation within cardiac
cells because dobutamine was able to revert to positive
the negative part of the basal FF relationship in accor-
dance with data previously obtained from terminally
failing human ventricular myocardium.28 Further stud-
ies are now needed to clarify the mechanisms involved
in the bimakalim-dobutamine interaction.
Limits of in vitro experimental models have to be
considered. First, mechanical abnormalities, as seen
in this model, may be different from contractile dys-
function caused by regional ischemia in in vivo mod-
els, which use the recovery of segmental wall func-
tion as an index of stunning. However, the reversibility
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of contractility loss in human atrial trabeculae under
dobutamine challenge fulfills the definition of
stunned myocardium.5,17 Second, although atrial and
ventricular tissues have shown similar responses to
hypoxia12 and to positive inotropic stimulation,29
some tissue-related specificity may account for car-
diac cell responses to action of KATP channel activa-
tors.15,30 Clinical extrapolation of our findings must
therefore await further studies in human ventricular
muscle.
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